Senju Pharmaceutical and Novaliq close agreement for dry eye disease therapy
Pharmaceutical Technology
JUNE 14, 2023
The therapy has shown efficacy and safety in trials for patients with a history of dry eye disease and clinical Meibomian gland dysfunction. Its safety and efficacy have been demonstrated in numerous studies in Europe, the United States and China. to treat dry eye disease.
Let's personalize your content